SlideShare une entreprise Scribd logo
1  sur  15
Association of Regulatory Boards of Optometry  www.arbo.org
Ocular Health Complications occur when Contact Lenses are purchased without a valid Rx. ,[object Object],[object Object],[object Object],[object Object]
The FDA’s response to some of ARBO’s and AOA’s earlier findings ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
COMPLICATION(S) DUE TO CONTACT LENSES DISPENSED WITHOUT A VALID PRESCRIPTION REPORTING FORM   Tel: (314) 785-6000 • Fax: (866) 886-6164 • E-mail: arbo@arbo.org Reference Letters and/or Numbers for Your Personal Use Only: (which does not identify the individual patient) __Burning __Dry Eye __Conjunctivitis  __Foreign Body Sensation __Corneal Distortion  __Giant Papillary Conjunctivitis (GPC) __Corneal Edema  __Itching __Corneal Epithelial Defect  __Keratitis __Corneal Infiltrate __Neovascularization/Pannus __Corneal Opacity  __Ocular Inflammation __Corneal Ulcer  __Pain __Discharge  __Stinging __Other (please comment) Treatment Plan:  Outcome: __Lubricants  __Return to Pre-Incident Status __Antibacterial Topical/Oral  __Short Term Vision Loss __Antibacterial/Anti-Inflammatory/ __Permanent Vision Loss Topical/Oral __Surgical Intervention  __Penetrating Keratoplasty __Other (please comment)   __Other (please comment) Financial Impact to Patient/Health Care Resources Utilized Medical Costs (Out of Pocket)  $_________________ Medical Costs (Third Party Payer)  $_________________ Sick Days Lost  $_________________ Loss of Income due to Office Visit,  $_________________ Total or Partial Disability, etc. Date: ____________ Doctor: ______________ Phone:___________
Current Reported Results (n=234) CL Complication Signs and Symptoms : Corneal edema (37%) Stinging (36%) Neovascularization or pannus (36%)  Pain (35%)   Burning (35%)  Foreign body sensation (32%)  Corneal epithelial defect (32%)  Conjunctivitis (29%)
Current Reported Results (n=234) CL Complication Signs and Symptoms (continued) : Ocular inflammation (27%)   Corneal infiltrate (25%) Corneal distortion (23%)  Keratitis (21%)  Corneal ulcer (20%)   Giant Papillary Conjunctivitis  (GPC) (17%)  Dry eye (18%) Itching (13%)
Current Reported Results (n=234) CL Complication Signs and Symptoms (continued) : Discharge (12%)  Corneal opacity (12%)   Blurred vision (5%)  Iritis (1%)   The reported signs and symptoms that increased from the 2005 report were: conjunctivitis, corneal ulcer, and corneal opacity.
Current Reported Results (continued) CL Complication Treatment Plans required : Antibacterial/anti-inflammatory topical/oral meds (40%) Lubricants (33%) Antibacterial topical/oral meds (26%)  Refit correct contact lenses (9%)  Decrease/discontinue contact lens wear (5%)
Current Reported Results (continued) CL Complication Outcomes : Short-term vision loss (18%)  Returned to pre-incident status (18%) Permanent vision loss (8%) Permanent scarring (3%) Penetrating keratoplasty (1%)  Since 2005, Permanent vision loss increased.
Current Reported Results (continued) CL Complication’s cause financial impact:  Average Out of Pocket cost from patient  $98.18 Average Third Party Payment  for office visit's  $158.33 Average  Patient Loss of Income  $108.92 ---------------------------------------------------------------------------------- Total Cost per incidence  $365.43 Since 2005 Total costs increased 34%
ARBO supports on going Public Protection  ARBO realizes the ongoing research has provided important information to entities involved in setting health care policy, rules, and regulations for patient eye health.  ARBO encourages the Federal Government to continue its effort to police and eliminate the ability to purchase a contact lens without a valid prescription.
ARBO requests your help! ,[object Object]
The Political Landscape of contact lenses sold to the public without a verified prescription ,[object Object],[object Object],[object Object],[object Object]
The Political Landscape of contact lenses sold to the public without a verified prescription ,[object Object],[object Object]
Thank you ,[object Object],[object Object]

Contenu connexe

Similaire à ARBO Cl Complication Report

Practical Guide - www.devicematters.com
Practical Guide - www.devicematters.comPractical Guide - www.devicematters.com
Practical Guide - www.devicematters.comPowerViz
 
Dollars and Sense
Dollars and SenseDollars and Sense
Dollars and Senseeyedoc34
 
Ophthalmology Devices Global market
Ophthalmology Devices Global marketOphthalmology Devices Global market
Ophthalmology Devices Global marketPranesh Sujayeendra
 
Orthopedic Patents Current Trends, Innovations and Future Opportunities
Orthopedic Patents Current Trends, Innovations and Future OpportunitiesOrthopedic Patents Current Trends, Innovations and Future Opportunities
Orthopedic Patents Current Trends, Innovations and Future OpportunitiesJoseph Wyse
 
WTF@OIS: WHAT’S THE FUTURE @OIS?
WTF@OIS: WHAT’S THE FUTURE @OIS?WTF@OIS: WHAT’S THE FUTURE @OIS?
WTF@OIS: WHAT’S THE FUTURE @OIS?Healthegy
 
FDA the Gold Standard for Medical Device Safety
FDA the Gold Standard for Medical Device SafetyFDA the Gold Standard for Medical Device Safety
FDA the Gold Standard for Medical Device SafetyEMMAIntl
 
Medical device Industry 2015
Medical device Industry 2015Medical device Industry 2015
Medical device Industry 2015Rushikesh Markad
 
EGR 602 Medical Device Ethics Presentation
EGR 602 Medical Device Ethics PresentationEGR 602 Medical Device Ethics Presentation
EGR 602 Medical Device Ethics PresentationSayeed Mohammed
 
Brent Saunders
Brent SaundersBrent Saunders
Brent SaundersHealthegy
 
Adhesion Barriers Market by Product Type, Distribution Channel, End User 2024...
Adhesion Barriers Market by Product Type, Distribution Channel, End User 2024...Adhesion Barriers Market by Product Type, Distribution Channel, End User 2024...
Adhesion Barriers Market by Product Type, Distribution Channel, End User 2024...IMARC Group
 
Eye Disease Brochures
Eye Disease BrochuresEye Disease Brochures
Eye Disease Brochuresmepp
 
FDA Sterilization Innovation Challenge
FDA Sterilization Innovation ChallengeFDA Sterilization Innovation Challenge
FDA Sterilization Innovation ChallengeEMMAIntl
 
Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...
Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...
Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...IMARC Group
 
Organ Preservation Market Growth, Demand and Challenges of the Key Industry P...
Organ Preservation Market Growth, Demand and Challenges of the Key Industry P...Organ Preservation Market Growth, Demand and Challenges of the Key Industry P...
Organ Preservation Market Growth, Demand and Challenges of the Key Industry P...IMARC Group
 

Similaire à ARBO Cl Complication Report (20)

Practical Guide - www.devicematters.com
Practical Guide - www.devicematters.comPractical Guide - www.devicematters.com
Practical Guide - www.devicematters.com
 
Dollars and Sense
Dollars and SenseDollars and Sense
Dollars and Sense
 
SaferProducts.Gov
SaferProducts.GovSaferProducts.Gov
SaferProducts.Gov
 
Ophthalmology Devices Global market
Ophthalmology Devices Global marketOphthalmology Devices Global market
Ophthalmology Devices Global market
 
Orthopedic Patents Current Trends, Innovations and Future Opportunities
Orthopedic Patents Current Trends, Innovations and Future OpportunitiesOrthopedic Patents Current Trends, Innovations and Future Opportunities
Orthopedic Patents Current Trends, Innovations and Future Opportunities
 
WTF@OIS: WHAT’S THE FUTURE @OIS?
WTF@OIS: WHAT’S THE FUTURE @OIS?WTF@OIS: WHAT’S THE FUTURE @OIS?
WTF@OIS: WHAT’S THE FUTURE @OIS?
 
FDA the Gold Standard for Medical Device Safety
FDA the Gold Standard for Medical Device SafetyFDA the Gold Standard for Medical Device Safety
FDA the Gold Standard for Medical Device Safety
 
Co management with o ds2
Co management with o ds2Co management with o ds2
Co management with o ds2
 
Medical device Industry 2015
Medical device Industry 2015Medical device Industry 2015
Medical device Industry 2015
 
Medicortex ppp june 2021
Medicortex ppp june 2021Medicortex ppp june 2021
Medicortex ppp june 2021
 
Medicortex ppp may 2021
Medicortex ppp may 2021Medicortex ppp may 2021
Medicortex ppp may 2021
 
EGR 602 Medical Device Ethics Presentation
EGR 602 Medical Device Ethics PresentationEGR 602 Medical Device Ethics Presentation
EGR 602 Medical Device Ethics Presentation
 
Brent Saunders
Brent SaundersBrent Saunders
Brent Saunders
 
Taron. RO5.16.news
Taron. RO5.16.newsTaron. RO5.16.news
Taron. RO5.16.news
 
Adhesion Barriers Market by Product Type, Distribution Channel, End User 2024...
Adhesion Barriers Market by Product Type, Distribution Channel, End User 2024...Adhesion Barriers Market by Product Type, Distribution Channel, End User 2024...
Adhesion Barriers Market by Product Type, Distribution Channel, End User 2024...
 
Eye Disease Brochures
Eye Disease BrochuresEye Disease Brochures
Eye Disease Brochures
 
FDA Sterilization Innovation Challenge
FDA Sterilization Innovation ChallengeFDA Sterilization Innovation Challenge
FDA Sterilization Innovation Challenge
 
N8 Display PPT
N8 Display PPTN8 Display PPT
N8 Display PPT
 
Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...
Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...
Dry Eye Syndrome Market by Product Type, Distribution Channel, End User 2024-...
 
Organ Preservation Market Growth, Demand and Challenges of the Key Industry P...
Organ Preservation Market Growth, Demand and Challenges of the Key Industry P...Organ Preservation Market Growth, Demand and Challenges of the Key Industry P...
Organ Preservation Market Growth, Demand and Challenges of the Key Industry P...
 

ARBO Cl Complication Report

  • 1. Association of Regulatory Boards of Optometry www.arbo.org
  • 2.
  • 3.
  • 4. COMPLICATION(S) DUE TO CONTACT LENSES DISPENSED WITHOUT A VALID PRESCRIPTION REPORTING FORM Tel: (314) 785-6000 • Fax: (866) 886-6164 • E-mail: arbo@arbo.org Reference Letters and/or Numbers for Your Personal Use Only: (which does not identify the individual patient) __Burning __Dry Eye __Conjunctivitis __Foreign Body Sensation __Corneal Distortion __Giant Papillary Conjunctivitis (GPC) __Corneal Edema __Itching __Corneal Epithelial Defect __Keratitis __Corneal Infiltrate __Neovascularization/Pannus __Corneal Opacity __Ocular Inflammation __Corneal Ulcer __Pain __Discharge __Stinging __Other (please comment) Treatment Plan: Outcome: __Lubricants __Return to Pre-Incident Status __Antibacterial Topical/Oral __Short Term Vision Loss __Antibacterial/Anti-Inflammatory/ __Permanent Vision Loss Topical/Oral __Surgical Intervention __Penetrating Keratoplasty __Other (please comment) __Other (please comment) Financial Impact to Patient/Health Care Resources Utilized Medical Costs (Out of Pocket) $_________________ Medical Costs (Third Party Payer) $_________________ Sick Days Lost $_________________ Loss of Income due to Office Visit, $_________________ Total or Partial Disability, etc. Date: ____________ Doctor: ______________ Phone:___________
  • 5. Current Reported Results (n=234) CL Complication Signs and Symptoms : Corneal edema (37%) Stinging (36%) Neovascularization or pannus (36%) Pain (35%) Burning (35%) Foreign body sensation (32%) Corneal epithelial defect (32%) Conjunctivitis (29%)
  • 6. Current Reported Results (n=234) CL Complication Signs and Symptoms (continued) : Ocular inflammation (27%) Corneal infiltrate (25%) Corneal distortion (23%) Keratitis (21%) Corneal ulcer (20%) Giant Papillary Conjunctivitis (GPC) (17%) Dry eye (18%) Itching (13%)
  • 7. Current Reported Results (n=234) CL Complication Signs and Symptoms (continued) : Discharge (12%) Corneal opacity (12%) Blurred vision (5%) Iritis (1%) The reported signs and symptoms that increased from the 2005 report were: conjunctivitis, corneal ulcer, and corneal opacity.
  • 8. Current Reported Results (continued) CL Complication Treatment Plans required : Antibacterial/anti-inflammatory topical/oral meds (40%) Lubricants (33%) Antibacterial topical/oral meds (26%) Refit correct contact lenses (9%) Decrease/discontinue contact lens wear (5%)
  • 9. Current Reported Results (continued) CL Complication Outcomes : Short-term vision loss (18%) Returned to pre-incident status (18%) Permanent vision loss (8%) Permanent scarring (3%) Penetrating keratoplasty (1%) Since 2005, Permanent vision loss increased.
  • 10. Current Reported Results (continued) CL Complication’s cause financial impact: Average Out of Pocket cost from patient $98.18 Average Third Party Payment for office visit's $158.33 Average Patient Loss of Income $108.92 ---------------------------------------------------------------------------------- Total Cost per incidence $365.43 Since 2005 Total costs increased 34%
  • 11. ARBO supports on going Public Protection ARBO realizes the ongoing research has provided important information to entities involved in setting health care policy, rules, and regulations for patient eye health. ARBO encourages the Federal Government to continue its effort to police and eliminate the ability to purchase a contact lens without a valid prescription.
  • 12.
  • 13.
  • 14.
  • 15.